Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EDIT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 2–6 Matrix Metrics)

EDIT Overall Winner 6-Pillar Tally: EDIT 5 – 1 FDMT Matrix Metrics: EDIT 2 – 6 FDMT

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 48.4/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. EDIT 48.4/100 HOLD), EDIT captures the overall institutional head-to-head verdict (2–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-167.0% vs. -222.7% operating margin) and revenue trajectory (+37.4% vs. +4505.6% YoY).
  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs FDMT
EDIT NASDAQ Head-to-Head Winner
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (EDIT 5 – 1 FDMT)

Columns: Metric · EDIT · FDMT
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 5.2x 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) +37.4% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M $96M
Market Cap $336.5M $669.3M
3. Profitability & Quality EDIT
Gross Margin -73.3% N/A
Operating Margin -167.0% -222.7%
Net Profit Margin -144.9% -208.6%
Return on Equity (ROE) -147.4% -56.7%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$110M -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $79M Net Cash $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 95.8% (38th %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.29x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (2) vs FDMT (6)
Institutional Metric EDIT FDMT Criterion Row Edge
Market Capitalization
Scale
$336.5M $669.3M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+37.4% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-167.0% -222.7% Higher Margin EDIT
Net Profit Margin
Profitability
-144.9% -208.6% Higher Margin EDIT
Return on Equity (ROE)
Capital Efficiency
-147.4% -56.7% Higher ROE FDMT
52-Week Range Position
Momentum
11% ($2–$4) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 1.89β · 90% Vol Lower Realized Risk FDMT
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
$50M $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +14.9 pp
EDIT: -18.94% · FDMT: -4.04%
3M Horizon FDMT +12.99 pp
EDIT: -33.85% · FDMT: -20.86%
6M Horizon FDMT +63.97 pp
EDIT: -24.7% · FDMT: +39.27%
1Y Horizon FDMT +38.33 pp
EDIT: -25.0% · FDMT: +13.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue FDMT Revenue EDIT Op. Margin FDMT Op. Margin Margin Leader
FY2018 $30M N/A -356.1% N/A EDIT
FY2019 $20M $10M -686.4% -729.4% EDIT
FY2020 $90M $10M -148.6% -424.0% EDIT
FY2021 $30M $20M -756.1% -395.5% FDMT
FY2022 $20M $0M -1146.3% -3516.5% EDIT
FY2023 $80M $20M -216.6% -544.6% EDIT
FY2024 $30M $0M -777.2% -507678.4% EDIT
FY2025 $40M $90M -394.9% -187.2% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, Editas Medicine, Inc. (EDIT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EDIT carries a Unified Composite Score of 48.4/100 (HOLD) at $1.91 (N/M Forward P/E, -167.0% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. EDIT 48.4/100 HOLD), EDIT captures the overall institutional head-to-head verdict (2–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-167.0% vs. -222.7% operating margin) and revenue trajectory (+37.4% vs. +4505.6% YoY). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

EDIT screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.